Bristol Myers Squibb has the first positive phase 3 results under its belt for mezigdomide, a second experimental drug in its much-trumpeted celmod development programme for multiple myeloma.

Steve Sanghera is the CEO and co-founder of Inventus. With over 20 years of experience in technology and telecommunications, his extensive experience has proved crucial to the success of Inventus. The ...

The FDA has issued updated guidance that aims to make it easier for drugmakers to bring biosimilars of patent-expired biologic drugs to market, in the hope of reducing medicine prices. In a pair of ...

GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy linerixibat, which is under regulatory review in most major pharma markets worldwide ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

We need to break free from the idea that giving to women’s advancement is a subtraction. Instead, we need to see advancing women as an intentional multiplication that benefits teams, organisations, ...

If the rest of 2026 continues in this vein, we may look back on January and February as the moment the sector recognised that ...

The two companies announced today that Hims & Hers will now be able to sell Novo Nordisk's injectable and oral semaglutide products, sold respectively as Ozempic for type 2 diabetes and Wegovy for ...

Ipsen said it will now pull Tazverik from the market in all countries where it has rights to the first-in-class, chemotherapy ...

AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...

Prasad was first appointed head of the FDA's Center for Biologics Evaluation and Research (CBER) in May 2025 – after his ...

STEM has spent nearly two decades supporting pharma companies with strategic insights. As Adam Boucher explained, the emergence of generative AI has opened new possibilities for analysing field ...